The natural history of interferon-α2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection

QJM: An International Journal of Medicine

Volumn 102, Issue 2, 2009, Pages 117-122

  Tran, Huy A ^a   Reeves, G E M ^a   Jones, T l ^b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LIOTHYRONINE; PEGINTERFERON ALPHA2B; RIBAVIRIN; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE DURATION; DOSE RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS C; HORMONE SUBSTITUTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; THYROID FUNCTION; THYROIDITIS; TREATMENT DURATION;

EID: 58949100927     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcn150     Document Type: Article

References (26)

1. Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin N Am 2007; 36:1051-66.
2. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Interferon-α-related thyroid disease: Pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 2004; 89:3656-61.
3. Prummel MF, Laurberg P. Interferon-α and autoimmune thyroid disease. Thyroid 2003; 13:547-51.
4. Wong V, Fu Xi-Li A, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol 2002; 56:793-8.
5. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database System Rev 2002; 2:CD00370.
6. Moncoucy X, Leymarie F, Delemer B, Levy S, Bernard-Chabert B, Bouche O, et al. Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol 2005; 29:339-45.
7. Kee KM, Lee CM, Wang JH, Tung HD, Changchien CS, Lu SN, et al. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis. J Gastroenterol Hepatol 2006; 21 319-26.
8. Dalgard O, Bjoro K, Hellum K, Byrvang B, Bjoro T, Haug E, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: No association with either interferon dosage or efficacy of therapy. J Intern Med 2002; 251:400-6.
9. Hsieh M-C, Yu M-L, Chuang W-L, Shin S-J, Dai C-Y, Chen S-C, et al. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000; 142:431-7.
10. Minelli R, Valli MA, Di Secli D, Finardi L, Chiodera P, Bertoni R, et al. Is steroid therapy needed in the treatment of destructive thyrotoxicosis induced by α-interferon in chronic hepatitis C? Horm Res 2005; 63:194-9.
11. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117:10-3.
12. Minelli R, Coiro V, Valli MA, Finardi L, Di Secli C, Bertoni R, et al Graves' disease in interferon-alpha-treated and untreated patients with chronic hepatitis C virus infection. J Investig Med 2005; 53:26-30.
13. Bohbot NL, Young J, Orgiazzi J, Buffet C, Francois M, Bernard-Chabert B, et al. Interferon-alpha-induced hyperthyroidism: A three-stage evolution from silent thyroiditis towards Graves' disease. Eur J Endocrinol 2006; 154:367-72.
14. Tran HA. Hepatitis C infection, treatment regimens, and thyroid function abnormalities. Endocrinologist 2007; 17:231-5.
15. Hoofnagle JH, Seeff LB. Peginterferon and Ribavirin for chronic hepatitis C. N Engl J Med 2006; 352:2444-51.
16. Lloyd AR, Jagger E, Post JJ, Crooks LA, Rawlinson WD, Hahn YS, et al Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol 2007; 85 24-32.
17. Tilg H. New insights into the mechanisms of interferon alpha: An immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112:1017-21.
18. Gowans EJ. Distribution of markers of hepatitis C virus infection throughout the body. Semin Liver Dis 2000; 20:85-102.
19. Tran HA, Jones TL, Batey RG. The spectrum of thyroid disease treated with alpha-2-beta interferon and ribavirin in an Australian population. BMC Endocr Disord 2005; 5:8.
20. Demers LM, Spencer CA. Laboratory support for the diagnosis and monitoring of thyroid disease, 2003. [www.nacb.org/Impg/ thyroid_Impg_pub.htm], Accessed 27 July 2008.
21. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification. Hepatology 2006; 43:661-72.
22. British Society of Gastroenterology. Clinical Guidelines on the management of hepatitis C. [www.bsg.org.uk/pdf_word_docs/ clinguidehepc.pdf] Accessed 28 July 2008.
23. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130:225-30.
24. Management of hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19:1-46.
25. Tran HA. The uncertain natural history of thyrotoxic patients treated with combination interferon alfa-2β and Ribavirin. Arch Intern Med 2005; 165:1072.
26. Panara R, Cruz M, Lyra L, T Cruz. Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus. J Viral Hepat 2000; 7:393-5.